Strophanthidin

Strophanthidin is a cardenolide cardiac glycoside derived from Strophanthus plants that exerts its primary effects by selectively inhibiting the Na+/K+-ATPase pump in cardiac muscle cells. This inhibition elevates intracellular sodium and calcium concentrations, producing a positive inotropic effect that strengthens myocardial contractions.

Origin & History

Strophanthidin is a cardiac glycoside extracted from traditional Chinese medicinal plants including Semen Lepidii (Descurainia sophia seeds) and Antiaris toxicaria (upas tree). It belongs to the cardenolide class of compounds, characterized by a steroid nucleus with a lactone ring, and represents the aglycone form without attached sugar moieties.

Historical & Cultural Context

Strophanthidin originates from traditional Chinese medicine, where plants like Semen Lepidii and Antiaris toxicaria have been used for heart failure treatment. Its use parallels the historical application of cardiac glycosides like digitalis, with K-strophanthin forms being employed clinically for congestive heart failure management.

Health Benefits

• Enhanced cardiac function in severe congestive heart failure - superior to digoxin in improving left ventricular function (RCT, PMID: 1423365)
• Improved exercise performance in advanced heart failure patients - demonstrated in 6-month trial (RCT, PMID: 8001300)
• Potential anticancer activity against lung adenocarcinoma - shown to induce apoptosis in A549 cells with IC50 of 0.51 μM (preliminary, in vitro only)
• Increased myocardial contractility through Na+/K+-ATPase inhibition - clinically observed inotropic effects
• Low cytotoxicity to normal cells - demonstrated selectivity with minimal effects on HEK293T cells at 3.02 μM (preliminary, in vitro)

How It Works

Strophanthidin binds with high affinity to the alpha-subunit of the Na+/K+-ATPase enzyme, blocking the efflux of sodium ions from cardiomyocytes. The resulting rise in intracellular Na+ reduces activity of the Na+/Ca2+ exchanger, causing calcium accumulation within the sarcoplasmic reticulum and increasing the force of myocardial contraction. Additionally, strophanthidin modulates downstream signaling cascades including Src kinase and EGFR transactivation pathways, which may contribute to both its cardiac effects and its observed antiproliferative activity in cancer cell lines.

Scientific Research

Two key clinical trials examined strophanthidin in heart failure: a double-blind crossover RCT (PMID: 1423365) in 20 patients showed K-strophanthidin superior to digoxin for left ventricular function, and a 6-month trial (PMID: 8001300) in 22 patients demonstrated improved pump function. Anticancer evidence remains preclinical, limited to in vitro studies on lung, breast, and liver cancer cell lines.

Clinical Summary

A randomized controlled trial (PMID: 1423365) demonstrated that strophanthidin produced superior improvements in left ventricular ejection fraction compared to digoxin in patients with severe congestive heart failure, establishing a clinically meaningful advantage over the standard-of-care cardiac glycoside. A separate 6-month RCT (PMID: 8001300) documented measurable gains in exercise performance in advanced heart failure patients receiving strophanthidin. Emerging in vitro and preclinical data suggest anticancer activity, though human clinical trial evidence for oncological applications remains absent. Overall, cardiac evidence is limited to small RCTs, and large-scale, long-term safety and efficacy trials in modern populations are lacking.

Nutritional Profile

Strophanthidin is not a nutrient or food substance; it is a cardenolide-type cardiac glycoside (aglycone) with the molecular formula C₂₃H₃₂O₆ and molecular weight of 404.50 g/mol. It contains no macronutrients (protein, carbohydrates, fat), fiber, vitamins, or minerals. Key bioactive characteristics: • Primary bioactive compound: Strophanthidin itself — a steroidal aglycone derived from hydrolysis of k-strophanthoside and other Strophanthus glycosides (e.g., cymarin, convallatoxin). • Source organisms: Seeds of Strophanthus kombe, Strophanthus gratus, and related Apocynaceae species; also found in Convallaria majalis (lily of the valley). • Structural features: 5β,14β-androstane skeleton with a β-unsaturated γ-butyrolactone ring (C-17), hydroxyl groups at C-3β, C-5β, and C-14β, and an aldehyde group at C-10 (distinguishing it from other cardenolides like digitoxigenin). • Mechanism of action: Potent inhibitor of Na⁺/K⁺-ATPase (sodium-potassium pump) with IC₅₀ values in the nanomolar to low micromolar range depending on isoform; binds to the α-subunit extracellular domain. • Pharmacologically active concentration range: Cardiac glycoside activity observed at ~10⁻⁸ to 10⁻⁶ M; anticancer IC₅₀ reported at ~0.51 μM in A549 cells. • Bioavailability notes: As an aglycone (sugar-free form), strophanthidin has relatively higher lipophilicity and oral absorption compared to its parent glycosides (e.g., ouabain/g-strophanthin), though oral bioavailability remains limited and variable. Historically administered parenterally. Hepatic metabolism is significant; plasma half-life is relatively short compared to digoxin. • Therapeutic index: Extremely narrow — the toxic dose is close to the therapeutic dose, consistent with all cardiac glycosides. Not classified as a dietary supplement or nutritional compound. Exclusively used as a pharmaceutical/research agent.

Preparation & Dosage

Clinical trials used intravenous K-strophanthidin administered daily in 10ml saline, though specific milligram doses were not reported in available abstracts. Anticancer in vitro studies used concentrations of 0.51 μM for 48-hour treatments. No standardized oral dosing or extract preparations have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hawthorn extract, CoQ10, L-carnitine, magnesium, taurine

Safety & Interactions

Strophanthidin carries a narrow therapeutic index similar to other cardiac glycosides, with toxicity manifesting as bradycardia, heart block, ventricular arrhythmias, nausea, and visual disturbances at supratherapeutic exposures. Co-administration with antiarrhythmics such as amiodarone, calcium channel blockers, or other Na+/K+-ATPase inhibitors like digoxin significantly increases risk of additive cardiotoxicity and is contraindicated without close monitoring. Hypokalemia, hypomagnesemia, and hypercalcemia potentiate strophanthidin toxicity by sensitizing the Na+/K+-ATPase to inhibition, requiring electrolyte monitoring during use. Safety in pregnancy and lactation has not been established in controlled human studies, and strophanthidin should be avoided in these populations absent compelling clinical necessity.